More about cardiovascular disease and lipid management in New Zealand

New Zealand Medical Journal

Volumn 115, Issue 1163, 2002, Pages

  Metcalfe, Scott ^a   Moodie, Peter ^a  

^a Pharmaceutical Management Agency   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; COST OF ILLNESS; DRUG COST; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; NEW ZEALAND; OUTCOMES RESEARCH; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; REVIEW; BLOOD; FEMALE; MALE; NOTE;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; MALE; NEW ZEALAND;

EID: 0037064350     PISSN: 11758716     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Ellis CJ, Scott R. Cardiovascular disease and lipid management in New Zealand: progress at last! NZ Med J 2002;115:197-9.
2. MRC/BHF Heart Protection Study. LIFE-SAVER: World's largest cholesterol-lowering trial reveals massive benefits for high-risk patients. Press Release 13 November 2001. http://www.ctsu.ox.ac.uk/~hps/pr.shtml Accessed October 2002.
3. Rosch PJ. Statins don't work by lowering lipids. 16 November 2001. Kendrick M. Finally, proof that statins don't work by lowering LDL. 19 November 2001. Electronic responses to: Kmietowicz Z. Statins are the new aspirin, Oxford researchers say. BMJ 2001;323:1145. http://bmj.com/cgi/eletters/323/7322/1145#17583 Accessed October 2002.
4. PHARMAC. Updated statin cost utility analysis, January 2002) http://www.pharmac.govt.nz/download/statin02CUA.pdf Accessed 1 July 2002.
5. Freemantle N, Hill S. Medicalisation, limits to medicine, or never enough money to go around? BMJ 2002;324:864-5. http://bmj.com/cgi/content/full/324/7342/864 Accessed October 2002.
6. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996;312:1443-8.
7. Ebrahim S, Smith G, McCabe C, et al. What role for statins? A review and economic model. Health Technol Assess. 1999;3:i-iv, 1-91. http://www.hta.nhsweb.nhs.uk/fullmono/mon319.pdf Accessed 1 June 2002.
8. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32.
9. Bennett W, McNee W, Metcalfe S, Wright JM. Use of statins. In New Zealand, subsidy of statins is limited to particular groups of patients. BMJ 1997;315:1616.
10. Scott Metcalfe. Statins CUA for consideration by PHARMAC Board May 1997. 1 Methods. PHARMAC web site ("What's new") at http://www.pharmac.govt.nz/new/index.html, specific URL: http://www.pharmac.govt.nz/download/statin97methods.pdf Accessed October 2002.
11. Scott Metcalfe. Statins CUA for consideration by PHARMAC Board May 1997. 2 Results (broad summary). PHARMAC web site ("What's new") at http://www.pharmac.govt.nz/new/index.html, specific URL: http://www.pharmac.govt.nz/download/statin97results.pdf Accessed October 2002.
12. Scott Metcalfe. Updated cost utility analysis for statins, for PHARMAC consultation January 2002. PHARMAC web site ("What's new") at http://www.pharmac.govt.nz/new/index.html, specific URL: http://www.pharmac.govt.nz/download/statin02CUA.pdf Accessed October 2002.